Biotech & Pharma companies have a data problem. Biomedical data sets and scientific literature are densely full of knowledge and quickly growing. Even as scientists get more and more specialized, it is difficult and resource intensive for organizations to remain up to date with emerging and evolving information.
ERGO allows scientists to extract insights to make meaningful discoveries from the world’s biomedical knowledge. Explore what is known about a biomedical entity such as a gene, disease, or drug, to answer questions and discover new connections. Proprietary data can be integrated to put results in context of what is known. ERGO creates a unified set of analysis and ML-ready biomedical data to accelerate and de-risk drug development pipelines, especially in target validation, for biomedical teams needing faster, actionable insights from the vast set of biomedical data.
Accelerate identification, validation, and prioritization of novel drug targets
Quickly identify evidence for new drug targets, understand their relationship to diseases, suggest MOA and molecular pathways, and identify other therapeutics targeting similar diseases, pathways, and targets.
Analyze proprietary assays and data within the larger biological context
ERGO integrates proprietary data within the biological knowledge network allowing access to this larger biological context to assess significance, support graph diffusion analytics and enrichment analyses, and better interpret results.
Use our science-as-a-service team to accelerate your AI-driven drug development strategy
We use our ERGO platform to design bespoke data models and analyses targeted for our client’s proprietary focus areas. We customize and deploy our platform, within our clients’ environment, as an accelerator to create proprietary and differentiating drug development applications.
From strategy to deployment, we partner with you where you are in the AI/ML lifecycle.